(<0.1% PAL) is below theoretical estimates for the minimum O 2 requirements of the last common ancestor of bilaterians, measured limits at which bilaterians are found in the modern oceans, and threshold estimates for earlier diverging metazoan phyla (3, 4). In addition, it is possible that existing theoretical estimates of biological O 2 thresholds are biased toward low values, as they neglect the metabolic requirements of different life-history stages and synergistic physiological effects. In any case, our results suggest a temporal overlap between the appearance of stable environments favorable for animal life and the divergence of basal metazoan clades-which, according to recent estimates [e.g., (2)], occurred between~0.8 and 0.7 Ga (Fig. 3) . Though the emergence and eventual ecological dominance of animal life must, at its core, be tied to genetic and developmental innovations, our results implicate Earth's oxygen cycle as a crucial factor shaping the evolutionary landscape from which animal life emerged and help explain the delayed appearance of animals in the late Proterozoic.
Small molecules are useful tools for probing the biological function and therapeutic potential of individual proteins, but achieving selectivity is challenging when the target protein shares structural domains with other proteins. The Bromo and Extra-Terminal (BET) proteins have attracted interest because of their roles in transcriptional regulation, epigenetics, and cancer. The BET bromodomains (protein interaction modules that bind acetyl-lysine) have been targeted by potent small-molecule inhibitors, but these inhibitors lack selectivity for individual family members. We developed an ethyl derivative of an existing small-molecule inhibitor, I-BET/JQ1, and showed that it binds leucine/alanine mutant bromodomains with nanomolar affinity and achieves up to 540-fold selectivity relative to wild-type bromodomains. Cell culture studies showed that blockade of the first bromodomain alone is sufficient to displace a specific BET protein, Brd4, from chromatin. Expansion of this approach could help identify the individual roles of single BET proteins in human physiology and disease.
T he Bromo and Extra-Terminal (BET) proteins Brd2, Brd3, Brd4, and Brdt play key roles in transcriptional regulation by controlling networks of genes involved in cellular proliferation and cell-cycle regulation as part of multiprotein complexes. Misregulation of BET protein activity has been linked to disease states, notably in NUT-midline carcinoma and other cancers (1) . Key to the activity of BET proteins are paired, highly homologous bromodomains present in their amino-terminal regions (Fig. 1A) that direct recruitment to nucleosomes by specifically binding to acetylated lysines within histone tails. Elucidation of the complex biological processes controlled by BET proteins would benefit greatly from chemical probes that allow perturbation of individual bromodomains with high selectivity.
Potent cell-active small molecules based on a triazolodiazepine scaffold including I-BET (2), JQ1 (3), and GW841819X (4) (Fig. 1B) were recently discovered that bind to the acetyl-lysine (KAc) binding pocket of BET bromodomains [dissociation constant (K d ) 50 to 370 nM for I-BET] (Fig.  1C, table S1, and fig. S1 ). These molecules display activity in vivo (5) against NUT-midline carcinoma (6), multiple myeloma (7), mixed-lineage leukemia (8) , and acute myeloid leukemia (9, 10) . Several compounds, including I-BET, are now in clinical trials (11) . These and other inhibitors developed to date are pan-selective for the BET members relative to other bromodomains (3) but show poor selectivity within the subfamily (Fig. 1C) . Lack of selectivity confounds association of the pharmacology of BET bromodomain inhibitors to a particular target, which has fueled interest in finding more selective inhibitors. However, it is not clear which BET bromodomains should be the target of such an effort, and the high structural conservation and sequence identity of their KAc-binding sites hamper achievement of singletarget selectivity.
To address these problems, we hypothesized that a chemical genetic approach could be devised based on engineered shape complementarity between the bromodomain and a small-molecule inhibitor, allowing systematic generation of an orthogonal high-affinity protein-ligand variant pair. In a "bump-and-hole" strategy conceptually related to that developed to selectively target the adenosine 5´-triphosphate-binding site of protein kinases (12, 13) , a conserved hydrophobic residue on the bromodomain would be mutated to a smaller residue to generate a "hole" on the protein. The mutant would then be specifically targeted with analogs of a known ligand bearing a sterically bulky "bump" that can be accommodated by the pocket engineered on the mutant protein. Wildtype (WT) bromodomains would then bind the bulky analog more weakly as a result of a steric clash between the bump and the naturally occurring residue (Fig. 1D) .
We first inspected sequence alignments of the BET bromodomains ( Fig. 2A) and their crystal structures with bound I-BET, JQ1, and GW841819X ( Fig. 2B and fig. S2 ) to identify a suitable position for mutagenesis. These analyses revealed a leucine residue [L94 in Brd4 (1)] from the ZA loop that is strictly conserved throughout the BET subfamily and forms side-chain hydrophobic contacts with the inhibitors, thus providing a general strategy. To introduce a hole that could accommodate bumped ligands, we mutated leucine to an alanine (L/A). All L/A mutants displayed melting temperatures (T m ) above 40°C and thermal shifts (DT m ) within +1°and -3°C relative to wild type in differential scanning fluorimetry (DSF) (table S2) and showed overall similar binding profiles toward multi-acetylated histone H4 peptides compared with that of the respective wild type, by means of biolayer interferometry (BLI) ( fig. S3 ). Representative L/A mutants of both bromodomains of Brd2 and Brd4 as well as singly and doubly mutated tandem constructs retained the ability to bind to a tetra-acetylated H4 peptide in isothermal titration calorimetry (ITC), showing K d within five-to ninefold (first bromodomain) and 0.3-to 1.6-fold (second bromodomain) relative to that of the wild type (table S3) . Furthermore, singly and doubly mutated full-length Brd4 constructs conditionally expressed with tetracycline could restore c-Myc mRNA levels in a background of small interfering RNA knockdown of endogenous Brd4 in U2OS osteosarcoma cells (fig. S4) .
Together, these results demonstrate that L/A mutants of BET bromodomains are stable, retain KAc-specific histone binding, and can substitute for WT functionality.
Analyses of crystal structures suggested that functionalization of the side chain methylene of I-BET (Fig. 2C, red carbon) could provide a desired bump to fill the hole introduced by the L/A mutation. Docking studies suggested optimal substitutions to be in a (R)-configuration ( Fig. 2D and  fig. S5 ). To minimize alteration in electrostatics and physicochemical properties of the ligand scaffold, a methylester analog of I-BET was functionalized with alkyl groups at the R position (Fig. 2D) . Compounds ME (R = methyl) and ET (R = ethyl) were synthesized and tested by means of DSF and ITC to determine whether they are more selective for L/A than for WT proteins (Fig. 3, A and B) . Ligand ME bound to WT Brd2(1) and Brd2(2) with K d of 1.5 and 0.3 mM, respectively, which are a seven-and threefold weaker binding than I-BET as a result of introducing the bump. ME displayed K d of 17 and 22 nM (DT m of 7.9°and 9.3°C, respectively) against the corresponding L/A mutants, which are a 90-and 14-fold stronger binding relative to wild type. This promising selectivity profile was improved upon introducing a bulkier ethyl group. Compound ET showed K d s of 74 and 86 nM (DT m of 7.6°and 8.1°C) against Brd2(1) L110A and Brd2(2) L383A , respectively, which are 120-and 200-fold increases in affinity compared with wild type (K d , 9 and 17 mM) (Fig. 3, A and B) .
To validate our design strategy, we solved highresolution structures of Brd2(2) L383A apoprotein (apo) and in complex with ME and ET using x-ray crystallography (table S4 and S8, A and B) , positioning the respective methyl and ethyl substituents toward the hole introduced by the L/A mutation (Fig. 3, C and D, and fig. S8C ). In particular, the ethyl group of ET achieves optimal shape complementarity with the engineered pocket (Fig. 3D ) and desired steric clash against the Leu side chain present in the wild type ( fig. S8D) .
We next profiled selectivity across the entire BET bromodomain subfamily by characterizing the binding of ET to all WT and L/A mutant proteins by means of DSF (table S5) and ITC (Fig. 3, E  and F, table S5, and fig. S9 ). ET induced high thermal stabilization of all L/A mutants, with DT m ranging from 5.4°to 13.4°C, while stabilizing all WT proteins by less than 3°C (table S5) . Pleasingly, ET maintained high binding affinity toward all L/A mutants, with K d ranging from 36 to 200 nM (Fig. 3F ) and large favorable binding enthalpies DH from -8 to -22 kcal/mol (table S5) . Crucially, ET was notably less potent against WT bromodomains, with K d ranging from 6 to 19 mM (Fig. 3E) . A complete profile of ET binding affinity for L/A versus the wild type shows that binding selectivity of up to 540-fold and no less than 30-fold (average of 160-fold) is afforded across the subfamily (table S6) Statistical significance was determined with one-tailed t tests: *P < 0.05; **P < 0.01; ***P < 0.001; n.s. not significant.
results demonstrate that our orthogonal ET and L/A mutant pairs achieve tailored high selectivity at the level of individual bromodomains.
To further demonstrate the feasibility of targeting the L/A mutation selectively, we characterized binding affinities and stoichiometries of ET within the context of a tandem bromodomain construct of Brd2 using ITC (Fig. 4A) . In contrast to I-BET (K d = 360 nM and expected stoichiometry of 2:1), no binding of ET to wild type was observed (K d > 10 mM). The inactivity of ET against WT was further evidenced by its inability to induce upregulation of p21 mRNA levels, as reporter of downstream c-Myc activity (14) , when compared with I-BET treatment in U2OS cells ( fig. S10 ). However, ET exhibited K d of 140 to 150 nM for the two single L/A mutants and 24 nM for the double mutant, with the expected 1:1 and 2:1 stoichiometries, respectively, confirming potent and selective targeting of mutant versus WT bromodomain (Fig. 4A) .
To assess probe selectivity inside cells, we developed fluorescence recovery after photobleaching (FRAP) assays in U2OS cells transfected with full-length human Brd4. Control treatment with 1 mM I-BET accelerated the fluorescence recovery of the photobleached nuclear region of cells transfected with wild type (Fig. 4B, black, and fig. S11 ) relative to vehicle (Fig. 4B, white) , indicating displacement of Brd4 from chromatin, as reported with JQ1 (3). As expected, exposure with 1 mM ET against wild type showed no significant reduction of recovery times relative to vehicle-treated cells (Fig. 4B, purple) . Crucially, exposure of 1 mM ET against a double L(94,387)/A mutant showed recovery times comparable with the I-BET control in FRAP assays (Fig. 4B, red) , and similarly fast recoveries were seen when the first domain only was mutated (Fig. 4B, blue) but not the second (Fig. 4B, green) . Together, our data show that ET retains selectivity in cells and suggest that blockade of the first domain alone is sufficient to displace Brd4 from chromatin.
We describe a bump-and-hole approach to engineer controlled selectivity onto small-molecule modulation of BET bromodomains. We demonstrate that mutation of a conserved leucine residue within the bromodomain can be targeted by an ethyl derivative of I-BET with high potency and BET-subfamily selectivity in vitro and in cells. We also show proof of concept of applying orthogonal bromodomain:ligand pairs to dissect the role of individual bromodomains of Brd4 in chromatin binding. Future application of this approach could help identify which BET bromodomain target would be the most relevant therapeutic target in a given disease condition. To this end, recent advances in site-specific nuclease technologies for targeted genome engineering by use of clustered regulatory interspaced short palindromic repeat (CRISPR)/Cas9-based RNA-guided DNA endonucleases, among others (15, 16) , have opened up the possibility of systematically generating knock-in mutants in cells and living rodents (17) . If a desired selectivity cannot be achieved at the KAcbinding site of WT bromodomains, it could be achieved instead by targeting allosteric sites or by modulating other specific protein-protein interactions of BET multiprotein complexes. Last, our approach could be extended to engineer selective chemical control within other subfamilies of the human bromodomain phylogenetic tree.
